Sign up to save your podcasts
Or
Share Can we predict which patients will benefit from Tarceva based on a blood test?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Can we predict which patients will benefit from Tarceva based on a blood test?
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
View all episodes
By cancerGRACE - H. Jack West, MD
5
11 ratings
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
More shows like GRACEcast Lung Cancer Video
View all
GRACEcast Head and Neck Cancer Audio
2 Listeners
GRACEcast Radiation Oncology Audio
0 Listeners
GRACEcast Radiation Oncology Video
0 Listeners
GRACEcast Pancreatic Cancer Audio
0 Listeners
GRACEcast Pancreatic Cancer Video
1 Listeners
GRACEcast Cancer 101 Audio
0 Listeners
GRACEcast Bladder Cancer Video
0 Listeners
GRACEcast Head and Neck Cancer Video NEW
0 Listeners
GRACEcast Cancer 101 Video
0 Listeners